Near term it looks like a cost increase if users are taking more for adjustments than originally estimated. They need to see documented (and no, afrezzauser's site doesn't count) of the reduced A1c numbers before they'll be confident they will make it up on the back end.
They can solve the problem by directing Drs directly to suppliers. Maybe SNY bought Jones Medical. (for those not getting the reference, Jones Medical, early on, targeted their spirometry device to the Afrezza prescriber market.)
They're doing a soft launch because Exubera failed and they don't want to make the same mistakes.
No, your claiming Matt is being fiscally irresponsible for stating multiple times that a 35% profit split will equate to "roughly a mid twenties royalty".
I'm calling BS. SNY can't give them a spirometer. It's against the law. The can sell them one at a reasonable price but so could Jones Medical Devices. What ever is going on they are not waiting for SNY to"provide" the spirometer.
So with a 2M readership, how many are endos?
From the Diabetes Forecast media kit:
, that provides nearly 2 million readers
with trustworthy information and lifestyle
encouragement each month.
What's a joke is the fact you copy people's IDs to try and get any credibility for your posts. Sorry Bobby, but you're the joke.